Literature DB >> 34697627

Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months.

Domenico Ponticelli1, Ippazio C Antonazzo2, Grazia Caci3, Andrea Vitale1, Giovanni Della Ragione1, Maria L Romano1, Mario Borrelli1, Beniamino Schiavone1, Riccardo Polosa4,5, Pietro Ferrara2,6.   

Abstract

Entities:  

Keywords:  Pfizer COVID-19 vaccine; S-RBD-specific; SARS-CoV-2; decreasing immunity; immunoglobulins; neutralizing antibodies; seroconversion

Mesh：

Substances：

Year:  2021        PMID： 34697627     DOI： 10.1093/jtm/taab173

Source DB:  PubMed          Journal:  J Travel Med        ISSN： 1195-1982            Impact factor:   8.490


× No keyword cloud information.
  17 in total

1.  COVID-19 mRNA vaccine safety, immunogenicity, and effectiveness in a hospital setting: confronting the challenge.

Authors:  Luciana Albano; Vincenza Gianfredi; Janet Sultana; Grazia Caci; Giulia Hyeraci
Journal:  Intern Emerg Med       Date:  2022-01-27       Impact factor: 5.472

2.  Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals.

Authors:  Duaa W Al-Sadeq; Farah M Shurrab; Ahmed Ismail; Fathima Humaira Amanullah; Swapna Thomas; Nader Aldewik; Hadi M Yassine; Hanan F Abdul Rahim; Laith Abu-Raddad; Gheyath K Nasrallah
Journal:  J Travel Med       Date:  2021-12-29       Impact factor: 8.490

3.  Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies.

Authors:  P Ferrara; D Ponticelli; F Agüero; G Caci; A Vitale; M Borrelli; B Schiavone; I C Antonazzo; L G Mantovani; V Tomaselli; R Polosa
Journal:  Public Health       Date:  2022-02       Impact factor: 2.427

4.  Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up-Reply.

Authors:  Pietro Ferrara; Ippazio C Antonazzo; Riccardo Polosa
Journal:  Intern Emerg Med       Date:  2022-01-10       Impact factor: 5.472

5.  Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study.

Authors:  Farah M Shurrab; Duaa W Al-Sadeq; Haissam Abou-Saleh; Nader Al-Dewik; Amira E Elsharafi; Fatima M Hamaydeh; Bushra Y Abo Halawa; Tala M Jamaleddin; Huda M Abdul Hameed; Parveen B Nizamuddin; Fathima Humaira Amanullah; Hanin I Daas; Laith J Abu-Raddad; Gheyath K Nasrallah
Journal:  Vaccines (Basel)       Date:  2022-01-25

6.  Waning of Anti-SARS-CoV-2 Spike Antibody Levels 100 to 200 Days after the Second Dose of the BNT162b2 Vaccine.

Authors:  Hidenori Matsunaga; Hidefumi Takeuchi; Yuichiro Oba; Satoshi Fujimi; Tomoyuki Honda; Keizo Tomonaga
Journal:  Vaccines (Basel)       Date:  2022-01-24

7.  Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Onset Formation of Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, Celiac Disease and Antiphospholipid Syndrome.

Authors:  Christoph Thurm; Annegret Reinhold; Katrin Borucki; Sascha Kahlfuss; Eugen Feist; Jens Schreiber; Dirk Reinhold; Burkhart Schraven
Journal:  Vaccines (Basel)       Date:  2022-02-18

8.  Intensity and Dynamics of Anti-SARS-CoV-2 Immune Responses after BNT162b2 mRNA Vaccination: Implications for Public Health Vaccination Strategies.

Authors:  Matthaios Speletas; Ioanna Voulgaridi; Styliani Sarrou; Aikaterini Dadouli; Varvara A Mouchtouri; Dimitrios J Nikoulis; Maria Tsakona; Maria A Kyritsi; Athanasia-Marina Peristeri; Ioanna Avakian; Asimina Nasika; Paraskevi C Fragkou; Charalampos D Moschopoulos; Stamatia Zoubouneli; Ilias Onoufriadis; Lemonia Anagnostopoulos; Alexia Matziri; Georgia Papadamou; Aikaterini Theodoridou; Sotirios Tsiodras; Christos Hadjichristodoulou
Journal:  Vaccines (Basel)       Date:  2022-02-17

9.  Long Lasting Cellular Immune Response Induced by mRNA Vaccination: Implication for Prevention Strategies.

Authors:  Laura Vitiello; Lucia Gatta; Sara Ilari; Stefano Bonassi; Mario Cristina; Filippo Ciatti; Massimo Fini; Stefania Proietti; Patrizia Russo; Carlo Tomino; Dolores Limongi
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

10.  Patients with Liver Cirrhosis Show High Immunogenicity upon COVID-19 Vaccination but Develop Premature Deterioration of Antibody Titers.

Authors:  Katharina Willuweit; Alexandra Frey; Moritz Passenberg; Johannes Korth; Nissrin Saka; Olympia E Anastasiou; Birte Möhlendick; Andreas Schütte; Hartmut Schmidt; Jassin Rashidi-Alavijeh
Journal:  Vaccines (Basel)       Date:  2022-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.